BillionToOne: New Kid On The Molecular Diagnostics Block Poised To Take Share

BillionToOne, Inc. is disrupting molecular diagnostics, leveraging proprietary smNGS technology for rapid growth and a $5.2B market cap. BLLN's Unity Complete offers unmatched prenatal screening convenience and accuracy, bypassing paternal testing and expanding to 130 genes, outpacing competitors like Natera. Oncology testing is accelerating (176% y/y growth), with Northstar Response's Medicare coverage decision by end-2026 as a key catalyst.

Seeking Alpha • 6 hours ago

BillionToOne (BLLN) Reports Next Week: Wall Street Expects Earnings Growth

BillionToOne (BLLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 28, 2026

BillionToOne to Participate in Two Upcoming Investor Conferences

MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company will participate in two upcoming investor conferences.

GlobeNewsWire • Oct 27, 2026

BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026

MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

GlobeNewsWire • Oct 14, 2026

BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials

BillionToOne a molecular diagnostic company from California, has experienced quite a topsy-turvey journey since its debut in November last year. BLLN is set to hold on to a consistently high GMS of 70%, which reflects the capabilities of its unique QCT technology that underpins its oncology and prenatal diagnostics product suite. BLLN trades at a slight EV/sales discount to peers but offers best-in-class forward topline growth of 38% p.a., far outpacing the industry average of 22%.

Seeking Alpha • Oct 13, 2026

BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds

Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response

GlobeNewsWire • Oct 7, 2026

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, aiming to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually.

Benzinga • Sep 23, 2026

BillionToOne SVP Sells 1,416 Shares

The transaction involved 1,416 shares at a weighted average price of $97.54 per share, totaling $138,116 on Sept. 9, 2026. The sale involved shares equal to 5% of the direct equity position held before the transaction.

The Motley Fool • Sep 21, 2026

BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million

The transaction involved 30,331 shares executed at a weighted average price of $99.91 per share on September 14, 2026. The shares traded in this filing represented 100% of the insider's directly-held equity stake, and a portion belonging to his spouse.

The Motley Fool • Sep 17, 2026

BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference

MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference.

PRNewsWire • Sep 2, 2026